Literature DB >> 21555722

Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum.

Gilles W De Keulenaer1, Dirk L Brutsaert.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21555722     DOI： 10.1161/CIRCULATIONAHA.110.981431

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  36 in total

Review 1.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.

Authors:  Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 3.  A multidimensional sight on cardiac failure: uncovered from structural to molecular level.

Authors:  Vijay Urmaliya; Gustavo Franchelli
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

4.  CrossTalk opposing view: the late sodium current is not an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction).

Authors:  Zoltán Papp; Attila Borbély; Walter J Paulus
Journal:  J Physiol       Date:  2014-02-01       Impact factor: 5.182

5.  The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs. reduced ejection fraction.

Authors:  Matthew Nayor; Martin G Larson; Na Wang; Rajalakshmi Santhanakrishnan; Douglas S Lee; Connie W Tsao; Susan Cheng; Emelia J Benjamin; Ramachandran S Vasan; Daniel Levy; Caroline S Fox; Jennifer E Ho
Journal:  Eur J Heart Fail       Date:  2017-02-20       Impact factor: 15.534

6.  Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community.

Authors:  Jennifer E Ho; Philimon Gona; Michael J Pencina; Jack V Tu; Peter C Austin; Ramachandran S Vasan; William B Kannel; Ralph B D'Agostino; Douglas S Lee; Daniel Levy
Journal:  Eur Heart J       Date:  2012-04-16       Impact factor: 29.983

7.  Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.

Authors:  Selma F Mohammed; Barry A Borlaug; Véronique L Roger; Sultan A Mirzoyev; Richard J Rodeheffer; Julio A Chirinos; Margaret M Redfield
Journal:  Circ Heart Fail       Date:  2012-10-17       Impact factor: 8.790

8.  Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.

Authors:  David P Kao; James D Lewsey; Inder S Anand; Barry M Massie; Michael R Zile; Peter E Carson; Robert S McKelvie; Michel Komajda; John J V McMurray; JoAnn Lindenfeld
Journal:  Eur J Heart Fail       Date:  2015-08-06       Impact factor: 15.534

9.  Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.

Authors:  G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard
Journal:  Br J Pharmacol       Date:  2016-04-26       Impact factor: 8.739

10.  Interpatient Similarities in Cardiac Function: A Platform for Personalized Cardiovascular Medicine.

Authors:  Márton Tokodi; Sirish Shrestha; Christopher Bianco; Nobuyuki Kagiyama; Grace Casaclang-Verzosa; Jagat Narula; Partho P Sengupta
Journal:  JACC Cardiovasc Imaging       Date:  2020-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.